DUBLIN , Dec. 22, 2021 /PRNewswire/ -- The "North America PCR for Respiratory Infection Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type, Multiplex PCR, Traditional PCR, Digital PCR, Reverse-Transcriptase, and Others), Product Type, Infection Type, and End User" report has been added to ResearchAndMarkets.com's offering.
According to the report, the North America PCR for respiratory infection diagnostics market is expected to reach US$ 3,581.63 million by 2028 from US$ 1,766.10 million in 2021; it is estimated to grow at a CAGR of 10.6% from 2021 to 2028.
The growth of the market is determined due to some of the key driving factors, such as increasing burden of chronic respiratory diseases (CRDs) and growing developments in PCR testing, are expected to propel the growth of the market. However, availability of alternative assays is the major factor hindering the market growth. Chronic respiratory diseases (CRDs) are among the leading causes of morbidity globally due to the heavy consumption of tobacco. For instance, according to the WHO, in 2018, the fourth largest cause of mortality in the US was chronic lower respiratory illness, predominantly COPD. Nearly 15.7 million Americans (6.4%) have been diagnosed with COPD. The burden of CRDs is expected to increase in the future due to poor air quality, increase in addiction to smoking, and rise in geriatric population that is more prone to COPD and lung cancer.
Moreover, programs initiated in the countries to improve treatment and support the people living with respiratory diseases are likely to increase the demand for PCR for the diagnosis of respiratory diseases. This will lead to the market growth during the forecast period. The demand for PCR testing to diagnose infectious diseases has significantly risen in the past few years. The growing technological advancements have added an extra advantage of point-of-care testing through PCR, which has surged the demand for PCR diagnostics.
In addition, the demand has exponentially raised due to the outbreak of COVID-19. Since the pandemic has initiated, reverse transcription-polymerase reaction (RT-PCR) test has been preferably used to diagnose and examine the genetic material of SARS-CoV-2 RNA. The RT-PCR method is widely accepted as the gold standard for the detection of SARS-CoV-2 RNA due to its sensitive testing. Therefore, considering the demand for PCR testing, various market players have introduced PCR products and entered strategic developments in the global market. Also, most companies are now offering real-time polymerase chain reaction (PCR) tests for COVID-19, which is contributing to the growth of the target market. COVID-19 pandemic has served vital growth opportunities for the PCR for respiratory infection diagnostics market. The market has experienced exponential growth during the pandemic due to tremendous demand for COVID-19 testing through PCR. North America is the leading market that has significantly contributed to the growth of the market. There have been various factors, including increased incidences of COVID-19 positive patients, growth in PCR technologies, increasing production of reagents and kits, and many other factors.
The cases majorly led to the demand for PCR testing in the countries such as the US, Canada , and Mexico . In addition, companies such as Omega Laboratories and LaunchWorks are launching various PCR testing in countries expanding the services, due to increasing demand from governments, communities, and organizations to track and control the spread of the virus.
Key Topics Covered 1. Introduction 1.1 Scope of the Study 1.2 Research Report Guidance 1.3 Market Segmentation 2. North America PCR for Respiratory Infection Diagnostics Market - Key Takeaways 3. Research Methodology 3.1 Coverage 3.2 Secondary Research 3.3 Primary Research 4. PCR for Respiratory Infection Diagnostics Market - Market Landscape 4.1 Overview 4.2 PEST Analysis 4.2.1 North America - PEST Analysis 4.3 Experts Opinion 5. PCR for Respiratory Infection Diagnostics Market - Key Market Dynamics 5.1 Market Drivers 5.1.1 Increasing Burden of Chronic Respiratory Diseases (CRDs) 5.1.2 Growing Developments in PCR Testing 5.2 Market Restraints 5.2.1 Availability of Alternative Assays 5.3 Market Opportunities 5.3.1 Use of PCR Testing for Various Respiratory Infection Diagnostics 5.4 Future Trends 5.4.1 Developments in PCR Technology 5.5 Impact analysis 6. PCR for Respiratory Infection Diagnostics Market - North America Analysis 6.1 North America PCR for Respiratory Infection Diagnostics Market Revenue Forecast and Analysis
7. PCR for Respiratory Infection Diagnostics Market Analysis by Type 7.1 Overview 7.2 PCR for Respiratory Infection Diagnostics Market Revenue Share, by Type (2021 and 2028) 7.3 Real Time PCR (qPCR) 7.4 Multiplex PCR 7.5 Traditional PCR 7.6 Digital PCR 7.7 Reverse Transcriptase (RT-PCR) 7.8 Others
8. PCR for Respiratory Infection Diagnostics Market Analysis - By Product Type 8.1 Overview 8.2 PCR for Respiratory Infection Diagnostics Market, by Product Type 2021 & 2028 (%) 8.3 Reagents and kits 8.4 Instruments 8.5 Others
9. PCR for Respiratory Infection Diagnostics Market - By Infection Type 9.1 Overview 9.2 PCR for Respiratory Infection Diagnostics Market Revenue Share, by Infection Type, 2021 & 2028 (%) 9.3 Bacterial Infections 9.4 Viral Infection 9.5 Fungal and Other Pathogens
10. PCR for Respiratory Infection Diagnostics Market - By End User 10.1 Overview 10.2 PCR for Respiratory Infection Diagnostics Market Revenue Share, by End User (2021 and 2028) 10.3 Hospitals 10.4 Physician Clinics 10.5 Clinical Laboratories 10.6 Academic and Research Institutions 10.7 Biotech and Pharma Companies 10.8 Others
11. PCR for Respiratory Infection Diagnostics Market - North America Analysis 11.1 North America : PCR for Respiratory Infection Diagnostics Market
12. Impact of COVID-19 Pandemic on North America PCR for Respiratory Infection Diagnostics Market 12.1 North America : Impact Assessment of COVID-19 Pandemic
13. PCR for Respiratory Infection Diagnostics Market - Industry Landscape 13.1 Overview 13.2 Inorganic Growth Strategies 13.3 Organic Growth Strategies
14. Company Profiles 14.1 Abbott 14.2 F. Hoffmann-La Roche Ltd. 14.3 Hologic, Inc. 14.4 BD 14.5 Bio-Rad Laboratories Inc. 14.6 bioMerieux SA 14.7 QIAGEN 14.8 Thermo Fisher Scientific Inc. 14.9 Seegene Inc.
For more information about this report visit https://www.researchandmarkets.com/r/je8gn0
Research and Markets Laura Wood , Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/north-america-pcr-for-respiratory-infection-diagnostics-market-2021-2028-featuring-profiles-of-abbott-roche-hologic-bd-and-bio-rad-labs-among-other-key-players-301449752.html
We’re about to turn the page on the calendar, put 2021 behind us, and stride into the brave, new year of 2022 – and Wall Street’s prognosticators are busy scanning the stocks to find the winners and losers for next year’s markets. Whether it’s individual stocks, whole industry sectors, or some combination of both, the analysts are finding plenty of Buy-rated equities for investors to consider. Take the automotive sector. Few industrials will present as many investment opportunities, both in 2022
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...
Hundreds of Chinese companies are listed on U.S. markets. But which are the best Chinese stocks to buy or watch right now? JD.com , Nio, Li Auto, Xpeng and BYD Co.. China is the world's most-populous nation and the second-largest economy with a booming urban middle class and amazing entrepreneurial activity.
Will SPY continue the bull run in 2022 after the FED announced it will accelerate the reduction of its monthly bond purchases?
Some savers may want to 'double-up,' if you will and buy I Bonds before year end. Inflation-indexed savings bonds gain more interest as prices go up.
Mining companies have been minting bumper profits this year as metal and commodity prices skyrocket, and 2022 is set to become an even better year for miners
Trading was light across different crypto exchanges on Christmas day and Boxing Day in the U.K.; ether’s price was roughly flat.
The Federal Reserve’s expected interest-rate increases in the year ahead could make stock investors less willing to accept lofty valuations.
Fintech stocks have been in the spotlight this year as more companies go public via traditional initial public offerings or through merging with a special purpose acquisition company.
SPACs and venture capitalists are plowing money into startups at record rates, looking past worries about lofty valuations.
'Rich Dad Poor Dad' is as bearish as ever.
The Omicron strain weighed on mortgage rates going into the holidays. Rates are expected to rise, however, along side rising house prices to test demand.
Appoints Sagar Ahuja as Director and to the Board with the additional responsibility to lead QX Accounting Services as CEO
It’s a quiet day ahead on the economic calendar, with stats limited to French employment figures. The lack of stats will leave COVID-19 news in focus.
If you want to build momentum for your New Year’s money resolutions, set some financial improvements into motion before the end of the year.
The CEO of Connecticut-based Bridgewater Chocolate told Yahoo Finance that price and supply pressures haven't hit the company "yet."
Bitcoin’s price rose by more than 70% in 2021 despite the bearish sentiment in China, and more gains are expected over the coming year.
Yes, shares in Zoom Video soared during the coronavirus crisis. But what's the outlook for Zoom stock after the Five9 merger failed to close?
Shares of Alibaba Group Holding Ltd. rose 0.8% in morning trading Monday, after China's securities regulator's draft rules on overseas listings released over the long weekend OK'd the listing structure known as variable-interest entity (VIE) used by the e-commerce giant to list its shares on the NYSE. Alibaba's stock has now rallied 6.8% since closing at a 4 1/2-year low of $111.96 on Dec. 3, but was still down 20.4% over the past three months, and 48.6% year to date, while the S&P 500 has gaine
Kentucky's education system may have some ground to cover before Ford Motor Co. and SK Innovation open their twin battery plants in Hardin County.